Four Things Remedy Meds Does Differently — And One Thing to Read Before You Sign Up
The direct-to-consumer GLP-1 market has grown crowded enough that most platforms now look interchangeable from the outside: take a quiz, get reviewed, get shipped. The differences show up in the fine print — in what happens to your bill when your dose goes up, in whether you can reach a clinician on a Tuesday afternoon, in who pays for the bloodwork.
Remedy Meds, a subscription telehealth platform founded in 2024 and headquartered in Summit, New Jersey, has built its pitch around four of those details. Here’s what each one actually means in practice.
1. One monthly price, regardless of dose
Most GLP-1 patients start low and titrate up. On platforms that price by milligram or by dosage tier, that clinical progression doubles as a pricing escalator — the same program that looked affordable in month one can cost meaningfully more by month five.
Remedy Meds prices by medication instead of by dose. Compounded semaglutide runs $299 per month and compounded tirzepatide $399 per month, with the medication, provider support, and refills bundled into that single figure. There is no separate membership fee layered on top, and the subscription is billed month to month rather than as a prepaid multi-month block. Brand-name options are available on request at substantially higher prices — roughly $1,299 for Ozempic and $1,399 for Zepbound, subject to availability — and are filled at a local pharmacy rather than shipped by Remedy.
Two caveats worth naming. First, those figures sit at the higher end of the compounded market; several competitors undercut them. Second, Remedy does not publish standard-dose pricing openly on its site — a number surfaces after you complete the intake quiz, and the lowest publicly visible figure has been a microdose tier well below the standard rates. If flat pricing is the reason you’re considering the platform, confirm your specific number in writing before your first charge.
The company also does not accept insurance, though HSA and FSA funds generally apply.
2. Unlimited video calls and messaging
This is the feature that most clearly distinguishes Remedy from the low-cost end of the category, where “support” often means a message queue with a multi-day response window and a scheduled check-in once a month.
Remedy includes unlimited video appointments and unlimited messaging with its clinical team in the base subscription. You schedule through the patient portal or submit a question to a care team member at any time. For a drug class where the first eight weeks are frequently defined by nausea, dose-timing questions, and the judgment call of whether a side effect is normal or a reason to stop, unrestricted access is a substantive benefit rather than a marketing flourish.
The structural tradeoff: you are not assigned a dedicated primary provider. Access is to a care team, which means continuity across visits is not guaranteed. Forbes Health’s tester described her first provider as attentive and unhurried but reported a less satisfactory interaction with another — a reasonable illustration of what a rotating-team model looks like from the patient side.
3. Lab work at no additional cost
If your provider determines that bloodwork is needed, you can either submit recent results from the past two years or have labs drawn at a Quest, BioReference, or LabCorp location — at no cost beyond your membership fee.
This matters more than it might appear. Baseline and follow-up labs are part of responsible GLP-1 prescribing, and platforms that treat them as an unbundled add-on create a quiet financial incentive to skip them. Folding labs into the subscription removes that friction.
Note the conditional, though: labs are ordered when a provider deems them necessary, not automatically for every patient. This is not a program that includes a standing comprehensive panel by default.
4. Cold-chain shipping — with a distinction worth making
GLP-1 medications are temperature-sensitive, and Remedy ships through a cold-chain courier process at no additional charge.
Here the marketing and the documentation diverge, and the gap is worth being precise about. Remedy’s promotional materials advertise a 48-hour figure, and this is widely repeated — but it describes shipping time, not delivery time. Forbes Health’s editorial review, citing the company, reports that a four-week supply “should arrive within seven business days” once the prescription is processed. Tracking information is emailed, and refill forms can be submitted at the three-week mark to avoid gaps.
Fast dispatch is a real advantage, and many customers do report quick arrival — Remedy holds a 4.6 average across more than 12,000 Trustpilot reviews, with shipping speed among the most-cited positives. But “shipped within 48 hours” and “delivered in 48 hours” are different promises, and anyone budgeting their supply around the latter should plan for the seven-business-day window instead.
The thing to read before you sign up
On September 9, 2025, the FDA issued Remedy Meds a warning letter (MARCS-CMS 716830) citing misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The agency’s concern was advertising: Remedy’s website stated that its compounded semaglutide and tirzepatide contain the same active ingredients as brand-name GLP-1s in a way that implied the compounded products were FDA-approved. They are not.
Context matters in both directions. The letter was part of a broad FDA and HHS initiative announced that same day targeting misleading direct-to-consumer pharmaceutical advertising, and more than fifty GLP-1 compounders and telehealth marketers received similar letters over equivalency claims. It concerned marketing language, not a finding that any specific batch of medication was contaminated or unsafe, and it is not a court judgment. Companies routinely respond and remediate.
But it is a matter of public record, and it bears directly on how to read any promotional claim about this category — including the four above.
The underlying point the FDA was making is the one to carry forward: compounded medications are not FDA-approved. They are not evaluated for safety, efficacy, or quality before reaching patients, and the agency’s guidance is that they should be considered primarily when an approved alternative is unavailable. Compounded semaglutide and tirzepatide also carry the same boxed warning as their brand-name counterparts regarding the risk of thyroid C-cell tumors; anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not take them.
Customer sentiment is genuinely mixed, too. The Trustpilot average is strong, but Forbes Health’s consumer sentiment analysis found predominantly negative feedback across broader online forums — unfulfilled orders, unexpected charges, and communication problems were recurring themes — and the company’s Better Business Bureau rating has been poor.
The bottom line
Remedy Meds is built for someone who values predictable pricing and genuine access to clinicians, and who is willing to pay a premium over the cheapest compounded options to get both. Flat per-medication pricing, unlimited clinician contact, and included labs are real structural advantages, not repackaged industry standards.
They sit alongside real considerations: prices at the top of the compounded market, a rotating care team, a delivery claim that is more modest than it first sounds, and an FDA warning letter that is worth reading in full rather than taking anyone’s summary of it.
If you’re considering a GLP-1, the most useful step is still a conversation with a clinician who knows your history about whether an FDA-approved medication is accessible to you first — through insurance, a manufacturer savings program, or direct-purchase pricing from Novo Nordisk or Eli Lilly, both of which have expanded cash-pay options. Compounded telehealth is a reasonable path for many people. It should be a considered one.
This article is for general information and is not medical advice. Pricing and program details reflect publicly reported figures as of mid-2026 and change frequently; verify current terms directly with the provider.